JP2022512597A - 細胞精製を伴わない微生物分析 - Google Patents
細胞精製を伴わない微生物分析 Download PDFInfo
- Publication number
- JP2022512597A JP2022512597A JP2021518514A JP2021518514A JP2022512597A JP 2022512597 A JP2022512597 A JP 2022512597A JP 2021518514 A JP2021518514 A JP 2021518514A JP 2021518514 A JP2021518514 A JP 2021518514A JP 2022512597 A JP2022512597 A JP 2022512597A
- Authority
- JP
- Japan
- Prior art keywords
- cartridge
- sample
- well
- growth
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004458 analytical method Methods 0.000 title claims abstract description 82
- 230000000813 microbial effect Effects 0.000 title claims description 26
- 238000000746 purification Methods 0.000 title description 39
- 238000000034 method Methods 0.000 claims abstract description 367
- 238000009635 antibiotic susceptibility testing Methods 0.000 claims abstract description 148
- 244000005700 microbiome Species 0.000 claims abstract description 148
- 241000894007 species Species 0.000 claims abstract description 130
- 239000000523 sample Substances 0.000 claims description 308
- 210000004027 cell Anatomy 0.000 claims description 279
- 210000002700 urine Anatomy 0.000 claims description 173
- 230000012010 growth Effects 0.000 claims description 163
- 238000003384 imaging method Methods 0.000 claims description 139
- 239000004599 antimicrobial Substances 0.000 claims description 120
- 230000005291 magnetic effect Effects 0.000 claims description 76
- 238000001514 detection method Methods 0.000 claims description 59
- 238000011534 incubation Methods 0.000 claims description 54
- 238000002372 labelling Methods 0.000 claims description 48
- 239000003153 chemical reaction reagent Substances 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 28
- 239000011324 bead Substances 0.000 claims description 27
- 238000012546 transfer Methods 0.000 claims description 25
- 239000001963 growth medium Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 238000011068 loading method Methods 0.000 claims description 15
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 claims description 13
- 238000007901 in situ hybridization Methods 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 238000011895 specific detection Methods 0.000 claims description 9
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 8
- 239000002751 oligonucleotide probe Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 238000009640 blood culture Methods 0.000 claims description 2
- 210000003756 cervix mucus Anatomy 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000004915 pus Anatomy 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 50
- 238000012545 processing Methods 0.000 abstract description 27
- 230000001580 bacterial effect Effects 0.000 description 108
- 244000052769 pathogen Species 0.000 description 106
- 239000003242 anti bacterial agent Substances 0.000 description 99
- 230000003115 biocidal effect Effects 0.000 description 94
- 239000006249 magnetic particle Substances 0.000 description 94
- 241000894006 Bacteria Species 0.000 description 93
- 229940088710 antibiotic agent Drugs 0.000 description 93
- 238000003556 assay Methods 0.000 description 88
- 238000002815 broth microdilution Methods 0.000 description 82
- 239000002245 particle Substances 0.000 description 66
- 230000001717 pathogenic effect Effects 0.000 description 62
- 239000000203 mixture Substances 0.000 description 59
- 239000000872 buffer Substances 0.000 description 56
- 239000000975 dye Substances 0.000 description 50
- 230000005284 excitation Effects 0.000 description 49
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 48
- 208000015181 infectious disease Diseases 0.000 description 45
- 238000011282 treatment Methods 0.000 description 42
- 230000000845 anti-microbial effect Effects 0.000 description 40
- 241000588724 Escherichia coli Species 0.000 description 36
- 238000009396 hybridization Methods 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000003102 growth factor Substances 0.000 description 31
- 208000019206 urinary tract infection Diseases 0.000 description 28
- 239000004005 microsphere Substances 0.000 description 25
- 230000003287 optical effect Effects 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 229960003405 ciprofloxacin Drugs 0.000 description 24
- 238000011081 inoculation Methods 0.000 description 24
- 108010050327 trypticase-soy broth Proteins 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 229960000564 nitrofurantoin Drugs 0.000 description 22
- 239000001974 tryptic soy broth Substances 0.000 description 22
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 21
- 238000009826 distribution Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 230000008569 process Effects 0.000 description 18
- 230000010076 replication Effects 0.000 description 17
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 239000007850 fluorescent dye Substances 0.000 description 15
- 239000007983 Tris buffer Substances 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 14
- 150000001768 cations Chemical class 0.000 description 14
- 229960001139 cefazolin Drugs 0.000 description 14
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 14
- 229940047766 co-trimoxazole Drugs 0.000 description 13
- 238000007405 data analysis Methods 0.000 description 13
- 230000035484 reaction time Effects 0.000 description 13
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 12
- 238000005054 agglomeration Methods 0.000 description 12
- 244000052616 bacterial pathogen Species 0.000 description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 12
- 239000001046 green dye Substances 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 229920000805 Polyaspartic acid Polymers 0.000 description 11
- UZZFFIUHUDOYPS-UHFFFAOYSA-L disodium 4-amino-3,6-bis[[4-[(2,4-diaminophenyl)diazenyl]phenyl]diazenyl]-5-oxido-7-sulfonaphthalene-2-sulfonate Chemical compound [Na+].[Na+].Nc1ccc(N=Nc2ccc(cc2)N=Nc2c(N)c3c(O)c(N=Nc4ccc(cc4)N=Nc4ccc(N)cc4N)c(cc3cc2S([O-])(=O)=O)S([O-])(=O)=O)c(N)c1 UZZFFIUHUDOYPS-UHFFFAOYSA-L 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 108010064470 polyaspartate Proteins 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000194033 Enterococcus Species 0.000 description 10
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 10
- 238000005286 illumination Methods 0.000 description 10
- 229960003376 levofloxacin Drugs 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- 208000035473 Communicable disease Diseases 0.000 description 9
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 230000002906 microbiologic effect Effects 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 7
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 7
- 238000012733 comparative method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960002182 imipenem Drugs 0.000 description 7
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000007477 logistic regression Methods 0.000 description 7
- 238000013207 serial dilution Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 102100020743 Dipeptidase 1 Human genes 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000013095 identification testing Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- RUUHDEGJEGHQKL-UHFFFAOYSA-M 2-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].CC(O)C[N+](C)(C)C RUUHDEGJEGHQKL-UHFFFAOYSA-M 0.000 description 5
- -1 CDC87 Proteins 0.000 description 5
- 241000588923 Citrobacter Species 0.000 description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 241001025319 Etheostoma collis Species 0.000 description 5
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 5
- 229960004287 clofazimine Drugs 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 4
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000191938 Micrococcus luteus Species 0.000 description 4
- 241000219470 Mirabilis Species 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000013139 quantization Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 241000588748 Klebsiella Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- IABBAGAOMDWOCW-UHFFFAOYSA-N Nicametate citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)CCOC(=O)C1=CC=CN=C1 IABBAGAOMDWOCW-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000006150 trypticase soy agar Substances 0.000 description 3
- 230000009105 vegetative growth Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 108010068385 carbapenemase Proteins 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002260 meropenem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 210000004708 ribosome subunit Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241001232615 Acinetobacter baumannii ATCC 19606 = CIP 70.34 = JCM 6841 Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 102100031024 CCR4-NOT transcription complex subunit 1 Human genes 0.000 description 1
- 241000595586 Coryne Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102100033711 DNA replication licensing factor MCM7 Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000919672 Homo sapiens CCR4-NOT transcription complex subunit 1 Proteins 0.000 description 1
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 1
- 101000808784 Homo sapiens Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 description 1
- 241001545494 Klebsiella michiganensis KCTC 1686 Species 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- 241000982698 Prorodonopsis coli Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101100029577 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDC43 gene Proteins 0.000 description 1
- 101100248173 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RFC1 gene Proteins 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000007444 cell Immobilization Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000012295 fluorescence in situ hybridization assay Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- CZPDZQLCDXNFKZ-UHFFFAOYSA-N guanidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(N)=N.OC(=O)CC(O)(C(O)=O)CC(O)=O CZPDZQLCDXNFKZ-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 239000001964 microbiological growth medium Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
- C12Q1/20—Testing for antimicrobial activity of a material using multifield media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/025—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations having a carousel or turntable for reaction cells or cuvettes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/021—Adjust spacings in an array of wells, pipettes or holders, format transfer between arrays of different size or geometry
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/04—Exchange or ejection of cartridges, containers or reservoirs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/042—Caps; Plugs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0636—Integrated biosensor, microarrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/087—Multiple sequential chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/065—Valves, specific forms thereof with moving parts sliding valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502738—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by integrated valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00346—Heating or cooling arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00346—Heating or cooling arrangements
- G01N2035/00356—Holding samples at elevated temperature (incubation)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/04—Details of the conveyor system
- G01N2035/0401—Sample carriers, cuvettes or reaction vessels
- G01N2035/0429—Sample carriers adapted for special purposes
- G01N2035/0436—Sample carriers adapted for special purposes with pre-packaged reagents, i.e. test-packs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/04—Details of the conveyor system
- G01N2035/0439—Rotary sample carriers, i.e. carousels
- G01N2035/0446—Combinations of the above
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Fluid Mechanics (AREA)
- Robotics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
マイクロタイタープレートを使用する尿路感染症(UTI)の同定および抗微生物薬感受性試験/最小発育阻止濃度分析
抗微生物薬感受性試験:E.coli
新規な迅速な蛍光in situハイブリダイゼーションアッセイを使用するグラム陰性菌についての検出限界(LoD)
実験方法:
結果:
包括性:本発明の迅速FISH法を使用する細菌種の異なる株を検出および同定する
実験方法。
迅速等温FISHを使用する標的細菌の特異的検出
実験方法。
結果。
4種の別個の微生物を同時に同定するマルチプレックスFISH法
図26は、各々4つの入力細菌のうち1つに特異的な4つの色チャネルの各々において蛍光を検出した、完全な獲得されたイメージの一部分を示す。各スポットは、単一細胞または細胞の群に対応する。アルゴリズムを使用して、アーチファクト(例えば、破片)とは別個の意味ある物体を同定し、それらの物体を細胞として計数する。各細菌についての差し込み図でわかるように、類似の数の細胞が予想どおり検出されたが、それは、入力細胞濃度がおよそ同じだったからである。オーバーレイすると、これらのスポットは対応せず、これは、4つの異なる細菌標的で、異なる物体が予想どおり各チャネルにおいて観察されたことを示している。
バリエーション:
(実施例6)
機器上のカートリッジにおける臨床尿検体中のE.coliの自動化迅速AST
実験方法:
結果。
尿試料中の細菌についての迅速で正確な抗微生物薬感受性試験
実験方法。
結果。
細胞精製を使用しない臨床尿試料についての迅速で正確な自動AST結果
実験方法。
ASTカートリッジの調製-培地および抗微生物薬
3X SSC(0.45MのNaCl、0.045Mのクエン酸ナトリウム、pH7.5)(Sigma、カタログ番号S6639)、0.18%w/vのセトリミド、0.77%のCHAPSO(Sigma カタログ番号C3649)、0.72%のSB3-12(Sigma カタログ番号D0431)、および0.13Mのチオシアン酸グアニジン(Sigma、カタログ番号G9277)を含有するハイブリダイゼーション緩衝剤を調製した。トレハロース(Sigma、カタログ番号T9449)をこの混合物中に溶解させ、終濃度を10%w/vとした。このハイブリダイゼーション緩衝剤-トレハロース混合物を8.3μL体積のビーズ中で凍結乾燥させた。2つの8.3uLビーズを8つの試薬ウェルのそれぞれの中に入れた(カートリッジ上の位置について、図37を参照されたい)。
ASTカートリッジの調製-磁気粒子
試料をカートリッジ中に入れるための手順-尿の処理
試料をカートリッジ中に入れるための手順-試料をカートリッジ上に置く
自動分析器上でのASTカートリッジの実行
分析器のイメージングシステムおよびイメージングプロセス
尿検体における直接的な迅速AST法は、病原体濃度の変動に頑強である
実験手順。
結果。
細胞精製なしでの複数の細菌種を含有する尿臨床検体中の標的病原体のための迅速抗微生物薬感受性試験
実験手順。
結果。
迅速抗微生物薬感受性試験は、ベータ-ラクタマーゼを発現する細菌の存在下でラクタム系抗生物質について正確である
培養に基づく細胞精製なしでの尿中の細菌の正確な迅速抗微生物薬感受性試験
多微生物性の複数の標的についての迅速で正確なAST
実験手順。
自動化された機器中のカートリッジにおける単一検体中の複数の標的病原体の迅速で正確な検出
実験手順。
参照による組み込み
均等物
Claims (34)
- 抗微生物薬感受性試験のための方法であって、
多微生物検体を得るステップ;
前記検体をウェル中に分割するステップであって、少なくとも一部の前記ウェルが、異なる薬剤または異なる濃度の1種もしくは複数の薬剤を含む、ステップ;
前記ウェル中の前記検体をインキュベートして、前記異なる薬剤または異なる濃度の薬剤に応答した差次的成長を可能にするステップ;および
各ウェル中の特定の種の個々の細胞を計数して、前記特定の種の成長を阻害する薬剤または薬剤の濃度を同定するステップ
を含む、方法。 - 対照ウェルのインキュベーション後に抗微生物剤を含有しない前記対照ウェル中の細胞を計数するステップをさらに含む、請求項1に記載の方法。
- 各ウェル中で計数された細胞の数を前記対照ウェルからの計数と比較して、前記異なる薬剤または異なる濃度の薬剤に曝露された場合の微生物の生存率を決定するステップをさらに含む、請求項2に記載の方法。
- 前記インキュベートするステップが、種特異的な様式で微生物を蛍光標識するステップを含み、前記計数するステップが、各ウェルをイメージングするステップ、およびイメージ中の蛍光スポットを計数するステップを含む、請求項1に記載の方法。
- 前記標識するステップが、標的特異的なフルオロフォアで標識された核酸または核酸アナログプローブを使用し、前記計数するステップが、蛍光in situハイブリダイゼーションを利用する、請求項4に記載の方法。
- 前記ステップが、核酸増幅を含まない、請求項1に記載の方法。
- 前記インキュベートするステップが、約1時間未満続き、成長培地中で約40℃より低い温度で行われる、請求項1に記載の方法。
- 前記分割するステップ、インキュベートするステップおよび計数するステップが、前記ウェルを含むカートリッジを使用して行われる、請求項1に記載の方法。
- 前記検体の一部を前記カートリッジ中に移入するステップであって、前記カートリッジが、微生物結合性磁気ビーズを含む、ステップ;および
前記カートリッジを分析器にロードするステップであって、前記分析器が、磁石を使用して、前記微生物を前記検体の他の部分から分離し、イメージングサブシステムを使用して、前記計数するステップを行う、ステップ
をさらに含む、請求項8に記載の方法。 - 前記分析器が、空気式サブシステムを使用して、前記カートリッジ内で前記分割するステップを行い、
前記ウェルが、前記カートリッジ内にあり、前記異なる薬剤または異なる濃度の薬剤を予めロードされ、
前記分割するステップおよび前記インキュベートするステップの後、前記分析器が、前記ウェルの内容物を対応する試薬ウェルに移入して、そこでインキュベートされた検体を前記磁気結合性磁気ビーズおよび種特異的な検出可能な標識に曝露させる、請求項9に記載の方法。 - 前記分析器が、磁石を使用して、前記微生物結合性磁気ビーズおよび結合した個々の微生物を、前記カートリッジ内の検出表面に引き寄せる、請求項9に記載の方法。
- 前記磁石が、未結合の検出可能な標識を前記検出表面から排除する色素クッションを介して前記微生物結合性磁気ビーズを引き寄せる、請求項11に記載の方法。
- 前記分析器が、カルーセルおよび/または機械式カートリッジ運搬体を使用して、前記カートリッジをイメージングサブシステムに移動させて、前記計数するステップを行う、請求項11に記載の方法。
- 前記種特異的な検出可能な標識が、特定の種の微生物の核酸を標的化するようにハイブリダイズする蛍光核酸プローブを含む、請求項10に記載の方法。
- 前記インキュベートするステップおよび計数するステップが、前記分析器内で生理学的温度で実質的に蛍光in situハイブリダイゼーション(FISH)分析を達成する、請求項14に記載の方法。
- 前記微生物の成長を阻害する抗微生物剤を同定するステップが、前記インキュベートされた検体中の複合体の数を、インキュベートされていない検体中の複合体の数と比較するステップを含む、請求項23に記載の方法。
- 前記分析器が、前記カートリッジを使用して、差次的成長後の前記個々の微生物の種特異的な計数を行う、請求項9に記載の方法。
- ウェルが、カートリッジ内にあり、前記方法が、
前記検体の一部を前記カートリッジ中に移入するステップ、および前記カートリッジを前記分析器にロードするステップを含む、請求項1に記載の方法。 - 前記分析器が、前記カートリッジをマニピュレートして、分割するステップ、インキュベートするステップ、および計数するステップを行う、請求項18に記載の方法。
- 前記検体が、前記移入するステップの前に、ユーザーによる任意の化学試料または分子試料の調製技術を必要としない、請求項18に記載の方法。
- 前記移入するステップが、前記検体の一部を収集容器から前記カートリッジ上の試料ウェル中にピペッティングするステップを含む、請求項18に記載の方法。
- 前記検体が、全血、陽性血液培養物、血漿、血清、尿、痰、気管支肺胞洗浄液、気管内吸引物、糞便、直腸脳脊髄液、創傷、腹水、膿汁、リンパ、膣分泌物、鼻分泌物、および体組織検体からなる群から選択される、請求項1に記載の方法。
- 微生物の分析方法であって、
微生物を含む検体を得るステップ;
任意のコロニーもしくは細胞の精製または培養のステップを伴わずに、前記検体の一部をウェル中に移入するステップであって、前記ウェルが、種特異的な検出可能な標識および微生物結合性磁気ビーズを含む、ステップ;
磁石を使用して、イメージング表面上の前記ビーズを収集するステップ;ならびに
前記イメージング表面上の前記検出可能な標識をイメージングして、それにより前記検体の前記一部中の前記種の細胞の存在を決定するステップ
を含む、方法。 - 前記検体が、前記移入するステップの前に、ユーザーによる任意の化学試料または分子試料の調製技術を必要としない、請求項23に記載の方法。
- 標的微生物を、前記ウェル中で前記種特異的な検出可能な標識で標識するステップ;および
微生物を、前記微生物結合性磁気ビーズに結合させるステップ
をさらに含み、観察するステップが、未結合の検出可能な標識を洗い流すことなく、標識された磁石結合細胞をイメージングするステップを含む、請求項23に記載の方法。 - 前記標識された磁石結合細胞の個々の細胞を計数するステップをさらに含む、請求項25に記載の方法。
- 前記ウェルが、カートリッジ内に提供され、前記収集するステップおよびイメージングするステップが、前記ビーズおよび前記細胞が前記カートリッジ内にある間に起こる、請求項23に記載の方法。
- 前記カートリッジを、前記収集するステップおよびイメージングするステップを行う分析器にロードするステップをさらに含む、請求項27に記載の方法。
- 前記分析器が、前記標識された微生物をイメージングするための少なくとも1つのイメージングサブシステムを含む、複数のサブシステム;およびサブシステム間の試験カートリッジを輸送するために動作可能なカルーセルを含む、請求項28に記載の方法。
- 前記移入するステップが、前記検体を前記カートリッジの受け入れウェル中に移入するステップを含み、前記分析器が、前記検体を前記カートリッジ内の複数の分割ウェルに分割し、前記ウェルが、前記分割ウェルの1つである、請求項28に記載の方法。
- 前記種特異的な検出可能な標識が、前記種の前記細胞の核酸と特異的にハイブリダイズする蛍光標識されたオリゴヌクレオチドプローブを含む、請求項27に記載の方法。
- 前記イメージングするステップが、前記カートリッジ内で一定の生理学的温度での蛍光in situハイブリダイゼーション(FISH)分析を含む、請求項31に記載の方法。
- 前記イメージング表面上の前記ビーズを収集するステップが、色素クッションが未結合の検出可能な標識を前記イメージング表面から排除しながら、前記ウェル中の前記色素クッションを介して前記ビーズを磁気的に引き寄せるステップを含む、請求項27に記載の方法。
- 前記種の前記細胞が、移入するステップの約30分以内に、前記検体中に存在すると決定される、請求項23に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862741253P | 2018-10-04 | 2018-10-04 | |
US62/741,253 | 2018-10-04 | ||
PCT/US2019/054885 WO2020073016A1 (en) | 2018-10-04 | 2019-10-04 | Microbial analysis without cell purification |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512597A true JP2022512597A (ja) | 2022-02-07 |
JPWO2020073016A5 JPWO2020073016A5 (ja) | 2022-10-13 |
Family
ID=70054893
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518514A Pending JP2022512597A (ja) | 2018-10-04 | 2019-10-04 | 細胞精製を伴わない微生物分析 |
JP2021518615A Pending JP2022504269A (ja) | 2018-10-04 | 2019-10-04 | 細胞の検出および分析 |
JP2021518515A Pending JP2022512598A (ja) | 2018-10-04 | 2019-10-04 | 分析機器 |
JP2021518616A Pending JP2022512605A (ja) | 2018-10-04 | 2019-10-04 | 試験カートリッジ |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021518615A Pending JP2022504269A (ja) | 2018-10-04 | 2019-10-04 | 細胞の検出および分析 |
JP2021518515A Pending JP2022512598A (ja) | 2018-10-04 | 2019-10-04 | 分析機器 |
JP2021518616A Pending JP2022512605A (ja) | 2018-10-04 | 2019-10-04 | 試験カートリッジ |
Country Status (7)
Country | Link |
---|---|
US (4) | US20230235411A1 (ja) |
EP (4) | EP3861345A4 (ja) |
JP (4) | JP2022512597A (ja) |
CN (4) | CN113260371A (ja) |
AU (4) | AU2019354837A1 (ja) |
CA (4) | CA3115262A1 (ja) |
WO (4) | WO2020073018A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3837531A4 (en) * | 2018-08-17 | 2022-05-04 | Genefluidics, Inc. | GENERATION OF DATA FOR USE WITH ANTIMICROBIAL SUBSTANCES |
MX2022005186A (es) * | 2019-10-29 | 2022-08-08 | Quantum Si Inc | Sistemas y metodos para preparacion de muestras. |
JP7475848B2 (ja) * | 2019-11-29 | 2024-04-30 | シスメックス株式会社 | 細胞解析方法、細胞解析装置、細胞解析システム、及び細胞解析プログラム、並びに訓練された人工知能アルゴリズムの生成方法、生成装置、及び生成プログラム |
US20210162398A1 (en) * | 2019-12-03 | 2021-06-03 | RPI Consulting, LLC | Medical testing device |
EP4153970A1 (en) * | 2020-05-20 | 2023-03-29 | YSI, Inc. | Extended solid angle turbidity sensor |
KR102551052B1 (ko) | 2020-12-28 | 2023-07-04 | 주식회사 어큐노스 | 항생제 감수성 검사방법 및 장비 |
WO2024059305A1 (en) * | 2022-09-15 | 2024-03-21 | General Electric Company | Method and apparatus for using lyophilized reagent beads for antimicrobial susceptibility testing |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070925B1 (en) * | 1996-07-16 | 2006-07-04 | Gen-Probe Incorporated | Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe |
DE19916610A1 (de) * | 1998-05-22 | 1999-11-25 | Creatogen Biosciences Gmbh | Nachweis von Antibiotikumresistenzen in Mikroorganismen |
US6251624B1 (en) * | 1999-03-12 | 2001-06-26 | Akzo Nobel N.V. | Apparatus and method for detecting, quantifying and characterizing microorganisms |
DK1432786T3 (da) * | 2001-09-06 | 2009-10-26 | Rapid Micro Biosystems Inc | Hurtig detektion af replikerede celler |
ATE432347T1 (de) * | 2002-06-24 | 2009-06-15 | Exiqon As | Methoden und systeme zur detektion und isolation von nucleinsäuresequenzen |
EP1473370A3 (en) * | 2003-04-24 | 2005-03-09 | BioMerieux, Inc. | Genus, group, species and/or strain specific 16S rDNA Sequences |
EP2413136B1 (en) * | 2003-07-18 | 2013-07-03 | Bio-Rad Laboratories, Inc. | System and method for multi-analyte detection |
US20050152955A1 (en) * | 2003-12-16 | 2005-07-14 | Akhave Jay R. | Electrostatically self-assembled antimicrobial coating for medical applications |
US20180243741A1 (en) * | 2004-05-02 | 2018-08-30 | Fluidigm Corporation | Thermal reaction device and method for using the same |
ATE531818T1 (de) * | 2006-05-02 | 2011-11-15 | Univ Paris Curie | Methode zur bestimmung und auszählung von mikroorganismen |
CA2703299C (en) * | 2007-10-23 | 2015-10-13 | Wild Child | Anti-microbial composition |
DE102008024567A1 (de) * | 2008-05-21 | 2009-12-03 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin | Verfahren zur Messung einer Konzentration einer Messsubstanz in einer biologischen Probe |
WO2010036827A1 (en) * | 2008-09-24 | 2010-04-01 | Straus Holdings Inc. | Method for detecting analytes |
US20100081131A1 (en) * | 2008-10-01 | 2010-04-01 | Ach Robert A | Identification of microbes using oligonucleotide based in situ hybridization |
WO2010048511A1 (en) * | 2008-10-24 | 2010-04-29 | Becton, Dickinson And Company | Antibiotic susceptibility profiling methods |
US20120045748A1 (en) * | 2010-06-30 | 2012-02-23 | Willson Richard C | Particulate labels |
GB201015492D0 (en) * | 2010-09-16 | 2010-10-27 | Univ Edinburgh | Binding and non-binding polymers |
US9714943B2 (en) * | 2010-12-30 | 2017-07-25 | University Of South Florida | Methods and materials for capture antibody targeted fluorescent in-situ hybridization (CAT-FISH) |
CN104284984B (zh) * | 2012-02-29 | 2017-10-13 | 哈佛大学校长及研究员协会 | 抗生素药敏性的快速测试 |
US9052314B2 (en) * | 2013-03-14 | 2015-06-09 | Silver Lake Research Corporation | Biomarkers for detecting the presence of bacteria |
EP2969212A1 (en) * | 2013-03-15 | 2016-01-20 | Illumina, Inc. | System and method for generating or analyzing a biological sample |
US10130902B2 (en) * | 2013-12-04 | 2018-11-20 | Pocared Diagnostics Ltd. | Method and apparatus for processing and analyzing filtered particles |
EP2886660A1 (en) * | 2013-12-20 | 2015-06-24 | Rigas Tehniska universitate | A fluorescent in situ hybridization method for identification of a microorganism |
AU2016243656A1 (en) * | 2015-03-30 | 2017-11-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
EP3314007B1 (en) * | 2015-06-25 | 2024-01-24 | Native Microbials, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
EP4303312A3 (en) * | 2016-04-22 | 2024-03-13 | Selux Diagnostics, Inc. | Performing antimicrobial susceptibility testing and related systems and methods |
EP3301454B1 (en) * | 2016-10-03 | 2019-08-28 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
PL3551293T3 (pl) * | 2016-12-06 | 2022-05-23 | Microbedx, Inc. | Rnaza do lepszego wykrywania drobnoustrojów i badania wrażliwości na środki przeciwdrobnoustrojowe |
-
2019
- 2019-10-04 WO PCT/US2019/054887 patent/WO2020073018A2/en unknown
- 2019-10-04 WO PCT/US2019/054885 patent/WO2020073016A1/en unknown
- 2019-10-04 AU AU2019354837A patent/AU2019354837A1/en active Pending
- 2019-10-04 JP JP2021518514A patent/JP2022512597A/ja active Pending
- 2019-10-04 CA CA3115262A patent/CA3115262A1/en active Pending
- 2019-10-04 EP EP19868682.6A patent/EP3861345A4/en active Pending
- 2019-10-04 US US17/282,633 patent/US20230235411A1/en active Pending
- 2019-10-04 JP JP2021518615A patent/JP2022504269A/ja active Pending
- 2019-10-04 WO PCT/US2019/054888 patent/WO2020073019A2/en unknown
- 2019-10-04 CA CA3115287A patent/CA3115287A1/en active Pending
- 2019-10-04 WO PCT/US2019/054884 patent/WO2020073015A1/en unknown
- 2019-10-04 US US17/282,623 patent/US20230241603A1/en active Pending
- 2019-10-04 JP JP2021518515A patent/JP2022512598A/ja active Pending
- 2019-10-04 AU AU2019356023A patent/AU2019356023A1/en active Pending
- 2019-10-04 US US17/282,630 patent/US20220033889A1/en active Pending
- 2019-10-04 CN CN201980080457.9A patent/CN113260371A/zh active Pending
- 2019-10-04 EP EP19870007.2A patent/EP3860629A4/en active Pending
- 2019-10-04 CN CN201980080492.0A patent/CN113260712A/zh active Pending
- 2019-10-04 AU AU2019355198A patent/AU2019355198A1/en active Pending
- 2019-10-04 CA CA3115279A patent/CA3115279A1/en active Pending
- 2019-10-04 CN CN201980080506.9A patent/CN113287017A/zh active Pending
- 2019-10-04 US US17/282,627 patent/US20210349082A1/en active Pending
- 2019-10-04 EP EP19868337.7A patent/EP3860452A4/en active Pending
- 2019-10-04 CN CN201980080462.XA patent/CN113272654A/zh active Pending
- 2019-10-04 CA CA3115289A patent/CA3115289A1/en active Pending
- 2019-10-04 JP JP2021518616A patent/JP2022512605A/ja active Pending
- 2019-10-04 AU AU2019353145A patent/AU2019353145A1/en active Pending
- 2019-10-04 EP EP19868804.6A patent/EP3861357A4/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022512597A (ja) | 細胞精製を伴わない微生物分析 | |
Puttaswamy et al. | A comprehensive review of the present and future antibiotic susceptibility testing (AST) systems | |
Forrest | PNA FISH: present and future impact on patient management | |
Dunbar et al. | Diagnosis and management of bloodstream infections with rapid, multiplexed molecular assays | |
KR20200062321A (ko) | 샘플에서 온전한 미생물의 농도를 결정하는 방법 | |
Needs et al. | Challenges in microfluidic and point-of-care phenotypic antimicrobial resistance tests | |
Hensley et al. | An evaluation of the AdvanDx Staphylococcus aureus/CNS PNA FISH™ assay | |
Song et al. | Mini-review: Recent advances in imaging-based rapid antibiotic susceptibility testing | |
Lee et al. | Quantitative fluorescence in situ hybridization (FISH) of magnetically confined bacteria enables early detection of human bacteremia | |
Liu et al. | Comparative analysis of five inspection techniques for the application in the diagnosis and treatment of osteoarticular tuberculosis | |
US20190218591A1 (en) | Systems and methods for scheduling and sequencing automated testing procedures | |
US6051395A (en) | Method and compound for detecting low levels of microorganisms | |
US20100075298A1 (en) | Method for rapid identification and quantification of microorganisms | |
Tang et al. | Direct-on-target microdroplet growth assay for detection of bacterial resistance in positive blood cultures | |
Bourbour et al. | Efficacy of 16S rRNA variable regions high-resolution melt analysis for bacterial pathogens identification in periprosthetic joint infections | |
Morgan | Ten years of experience with peptide nucleic acid fluorescent in situ hybridization in the clinical microbiology laboratory | |
Mini et al. | Detection of Antimicrobial Resistance in Veterinary Bacterial Pathogens | |
Amábile-Cuevas | Basis for a cheap method for detecting bacteria and assessing their antibiotic susceptibility in urine samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221004 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221004 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240405 |